GlassScriptPhysician profile
Amy R Kulak
NPI 1689823783
$4,219.99
in general payments reported to CMS, 2019-2025
20 companies · $715 in 2025
The $715 reported for 2025 was more than what a typical Ophthalmic Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $299).
See the full distribution for Ophthalmic Plastic and Reconstructive Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $150 · 2020: $114 · 2021: $178 · 2022: $654 · 2023: $529 · 2024: $1,880 · 2025: $715.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,123.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lumenis Be INC | $1,321.05 | 2024 | Optilight |
| Horizon Therapeutics Plc | $561.29 | 2019-2023 | Tepezza |
| Amgen INC. | $420.02 | 2024-2025 | Tepezza |
| Abbvie INC. | $336.88 | 2022-2024 | |
| Tarsus Pharmaceuticals, INC. | $245.52 | 2024-2025 | Xdemvy |
| Allergan, INC. | $239.47 | 2020-2022 | |
| Revance Therapeutics, INC. | $236.47 | 2024-2025 | Daxxify |
| Sight Sciences, INC. | $204.66 | 2022-2025 | Sion Surgical Instrument, Omni Surgical System |
| Kala Pharmaceuticals, INC. | $165.72 | 2021 | |
| Merz North America, INC. | $127.76 | 2023 | Xeomin |
| Galderma Laboratories, L.P. | $113.72 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $84.14 | 2024 | Miebo, Xiidra |
| Sun Pharmaceutical Industries INC. | $56.39 | 2019-2022 | |
| Oyster Point Pharma, INC. | $18.92 | 2023 | Tyrvaya |
| New World Medical,INC. | $18.64 | 2025 | Kahook Dual Blade, Ahmed Glaucoma Valve, Streamline |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $15.14 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14.81 | 2019 | |
| Shire North American Group INC | $14.38 | 2019 | |
| Eyevance Pharmaceuticals LLC | $12.80 | 2019 | |
| Aerie Pharmaceuticals, INC. | $12.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Kulak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.